Colm O'Dushlaine1, Stephan Ripke1, Douglas M Ruderfer2, Steven P Hamilton3, Maurizio Fava4, Dan V Iosifescu2, Isaac S Kohane5, Susanne E Churchill5, Victor M Castro6, Caitlin C Clements4, Sarah R Blumenthal4, Shawn N Murphy6, Jordan W Smoller7, Roy H Perlis8. 1. Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge. 2. Icahn School of Medicine at Mount Sinai, New York, New York. 3. Department of Psychiatry, University of California, San Francisco, California. 4. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts. 5. Information Systems, Massachusetts General Hospital, Boston, Massachusetts. 6. Information Systems, Massachusetts General Hospital, Boston, Massachusetts; Laboratory of Computer Science and Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. 7. Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge; Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts. 8. Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge; Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts; Partners HealthCare System, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: rperlis@partners.org.
Abstract
BACKGROUND: While antidepressant treatment response appears to be partially heritable, no consistent genetic associations have been identified. Large, rare copy number variants (CNVs) play a role in other neuropsychiatric diseases, so we assessed their association with treatment-resistant depression (TRD). METHODS: We analyzed data from two genome-wide association studies comprising 1263 Caucasian patients with major depressive disorder. One was drawn from a large health system by applying natural language processing to electronic health records (i2b2 cohort). The second consisted of a multicenter study of sequential antidepressant treatments, Sequenced Treatment Alternatives to Relieve Depression. The Birdsuite package was used to identify rare deletions and duplications. Individuals without symptomatic remission, despite two antidepressant treatment trials, were contrasted with those who remitted with a first treatment trial. RESULTS: CNV data were derived for 778 subjects in the i2b2 cohort, including 300 subjects (37%) with TRD, and 485 subjects in Sequenced Treatment Alternatives to Relieve Depression cohort, including 152 (31%) with TRD. CNV burden analyses identified modest enrichment of duplications in cases (empirical p = .04 for duplications of 100-200 kilobase) and a particular deletion region spanning gene PABPC4L (empirical p = .02, 6 cases: 0 controls). Pathway analysis suggested enrichment of CNVs intersecting genes regulating actin cytoskeleton. However, none of these associations survived genome-wide correction. CONCLUSIONS: Contribution of rare CNVs to TRD appears to be modest, individually or in aggregate. The electronic health record-based methodology demonstrated here should facilitate collection of larger TRD cohorts necessary to further characterize these effects.
BACKGROUND: While antidepressant treatment response appears to be partially heritable, no consistent genetic associations have been identified. Large, rare copy number variants (CNVs) play a role in other neuropsychiatric diseases, so we assessed their association with treatment-resistant depression (TRD). METHODS: We analyzed data from two genome-wide association studies comprising 1263 Caucasian patients with major depressive disorder. One was drawn from a large health system by applying natural language processing to electronic health records (i2b2 cohort). The second consisted of a multicenter study of sequential antidepressant treatments, Sequenced Treatment Alternatives to Relieve Depression. The Birdsuite package was used to identify rare deletions and duplications. Individuals without symptomatic remission, despite two antidepressant treatment trials, were contrasted with those who remitted with a first treatment trial. RESULTS: CNV data were derived for 778 subjects in the i2b2 cohort, including 300 subjects (37%) with TRD, and 485 subjects in Sequenced Treatment Alternatives to Relieve Depression cohort, including 152 (31%) with TRD. CNV burden analyses identified modest enrichment of duplications in cases (empirical p = .04 for duplications of 100-200 kilobase) and a particular deletion region spanning gene PABPC4L (empirical p = .02, 6 cases: 0 controls). Pathway analysis suggested enrichment of CNVs intersecting genes regulating actin cytoskeleton. However, none of these associations survived genome-wide correction. CONCLUSIONS: Contribution of rare CNVs to TRD appears to be modest, individually or in aggregate. The electronic health record-based methodology demonstrated here should facilitate collection of larger TRD cohorts necessary to further characterize these effects.
Authors: Holly A Garriock; Jeffrey B Kraft; Stanley I Shyn; Eric J Peters; Jennifer S Yokoyama; Gregory D Jenkins; Megan S Reinalda; Susan L Slager; Patrick J McGrath; Steven P Hamilton Journal: Biol Psychiatry Date: 2010-01-15 Impact factor: 13.382
Authors: Marcus Ising; Susanne Lucae; Elisabeth B Binder; Thomas Bettecken; Manfred Uhr; Stephan Ripke; Martin A Kohli; Johannes M Hennings; Sonja Horstmann; Stefan Kloiber; Andreas Menke; Brigitta Bondy; Rainer Rupprecht; Katharina Domschke; Bernhard T Baune; Volker Arolt; A John Rush; Florian Holsboer; Bertram Müller-Myhsok Journal: Arch Gen Psychiatry Date: 2009-09
Authors: Teresa B Gibson; Yonghua Jing; Ginger Smith Carls; Edward Kim; J Erin Bagalman; Wayne N Burton; Quynh-Van Tran; Andrei Pikalov; Ron Z Goetzel Journal: Am J Manag Care Date: 2010-05 Impact factor: 2.229
Authors: Joseph T Glessner; Kai Wang; Patrick M A Sleiman; Haitao Zhang; Cecilia E Kim; James H Flory; Jonathan P Bradfield; Marcin Imielinski; Edward C Frackelton; Haijun Qiu; Frank Mentch; Struan F A Grant; Hakon Hakonarson Journal: PLoS One Date: 2010-12-01 Impact factor: 3.240
Authors: Joshua M Korn; Finny G Kuruvilla; Steven A McCarroll; Alec Wysoker; James Nemesh; Simon Cawley; Earl Hubbell; Jim Veitch; Patrick J Collins; Katayoon Darvishi; Charles Lee; Marcia M Nizzari; Stacey B Gabriel; Shaun Purcell; Mark J Daly; David Altshuler Journal: Nat Genet Date: 2008-09-07 Impact factor: 38.330
Authors: J Elia; X Gai; H M Xie; J C Perin; E Geiger; J T Glessner; M D'arcy; R deBerardinis; E Frackelton; C Kim; F Lantieri; B M Muganga; L Wang; T Takeda; E F Rappaport; S F A Grant; W Berrettini; M Devoto; T H Shaikh; H Hakonarson; P S White Journal: Mol Psychiatry Date: 2009-06-23 Impact factor: 15.992
Authors: Shaun M Purcell; Naomi R Wray; Jennifer L Stone; Peter M Visscher; Michael C O'Donovan; Patrick F Sullivan; Pamela Sklar Journal: Nature Date: 2009-07-01 Impact factor: 49.962
Authors: Eric J Peters; Susan L Slager; Jeffrey B Kraft; Greg D Jenkins; Megan S Reinalda; Patrick J McGrath; Steven P Hamilton Journal: PLoS One Date: 2008-04-02 Impact factor: 3.240
Authors: Erin C Dunn; Ruth C Brown; Yael Dai; Jonathan Rosand; Nicole R Nugent; Ananda B Amstadter; Jordan W Smoller Journal: Harv Rev Psychiatry Date: 2015 Jan-Feb Impact factor: 3.732
Authors: Thomas H McCoy; Victor M Castro; Kamber L Hart; Amelia M Pellegrini; Sheng Yu; Tianxi Cai; Roy H Perlis Journal: Biol Psychiatry Date: 2018-02-26 Impact factor: 13.382
Authors: Xianglong Zhang; Abdel Abdellaoui; James Rucker; Simone de Jong; James B Potash; Myrna M Weissman; Jianxin Shi; James A Knowles; Carlos Pato; Michele Pato; Janet Sobell; Johannes H Smit; Jouke-Jan Hottenga; Eco J C de Geus; Cathryn M Lewis; Henriette N Buttenschøn; Nick Craddock; Ian Jones; Lisa Jones; Peter McGuffin; Ole Mors; Michael J Owen; Martin Preisig; Marcella Rietschel; John P Rice; Margarita Rivera; Rudolf Uher; Pablo V Gejman; Alan R Sanders; Dorret Boomsma; Brenda W J H Penninx; Gerome Breen; Douglas F Levinson Journal: Biol Psychiatry Date: 2019-03-13 Impact factor: 13.382